Unlocking the Potential of CCDC90B: A Drug Target and Biomarker

Target Name: CCDC90B

NCBI ID: G60492

CCDC90B

Unlocking the Potential of CCDC90B: A Drug Target and Biomarker

Introduction

The protein CCDC90B, also known as Coiled-coil domain containing 90B, has garnered significant attention due to its unique structure and biology. CCDC90B is a 90kDa protein that is primarily localized to the endoplasmic reticulum (ER) and is involved in various cellular processes, including cell signaling, DNA replication, and stress response. Its functional importance is reflected in its presence in numerous disease-related processes, including neurodegenerative diseases, cancer, and autoimmune disorders. As a result, CCDC90B has become an attractive drug target and a promising biomarker for a variety of diseases.

Structure and Localization

The CCDC90B protein is characterized by its unique coiled-coil domain, which is responsible for its unique physical and functional properties. The coiled-coil domain is a transmembrane region that is composed of four 伪-helices and a terminal coil, which are believed to play a significant role in the regulation of protein stability and localization.

The CCDC90B protein is primarily localized to the ER, where it is involved in the formation and maintenance of the endoplasmic reticulum-associated protein (ERP) complex. This complex is known as the CCDC90B-ERP complex and is composed of various proteins, including CCDC90B , ERP1, and others. The ERP1 protein is known to interact with CCDC90B and is involved in the regulation of CCDC90B stability and localization to the ER.

Function and Disease association

The CCDC90B protein has been implicated in various diseases and disorders due to its involvement in various cellular processes. One of the most significant associations is its involvement in neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. These diseases are characterized by the progressive loss of brain cells and the presence of neurofibrillary tangles and neuroinclusions in the brain.

In addition to its involvement in neurodegenerative diseases, CCDC90B has also been linked to the development and progression of cancer. The CCDC90B protein has been shown to be involved in cell signaling, DNA replication, and stress response, all of which are critical processes that are often disrupted in cancer cells. Therefore, CCDC90B has potential as a drug target and a biomarker for cancer.

CDC90B as a drug target

The CCDC90B protein is a potential drug target due to its unique structure and biology. Several studies have suggested that modifying the CCDC90B protein may be a viable strategy for the treatment of various diseases. One of the most promising strategies is the use of small molecules, such as inhibitors or modulators, to alter the activity of CCDC90B.

In addition to small molecules, the CCDC90B protein has also been the focus of attention due to the potential of gene therapy. Gene therapy involves the introduction of specific genes into cells to correct or treat genetic disorders. The CCDC90B gene has been targeted for gene therapy due to its potential to treat a variety of genetic disorders, including neurodegenerative diseases and cancer.

CDC90B as a biomarker

The CCDC90B protein has also been suggested as a potential biomarker for various diseases. Its unique structure and biology make it an attractive candidate for use as a biomarker. One of the most promising applications of CCDC90B as a biomarker is its potential to serve as a diagnostic marker for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

The CCDC90B protein is often a protein secreted by local anti-nerve cells, so it may serve as an indicator of peripheral blood activity of nerve cells. Furthermore, since C

Protein Name: Coiled-coil Domain Containing 90B

The "CCDC90B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC90B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets